A Phase I, Open-Label, Randomised, Single Dose, Crossover Pharmacokinetic Study Comparing a Capsule Formulation of BIT225 to the Current Oral Suspension Administered in Healthy Participants.

Trial Profile

A Phase I, Open-Label, Randomised, Single Dose, Crossover Pharmacokinetic Study Comparing a Capsule Formulation of BIT225 to the Current Oral Suspension Administered in Healthy Participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs BIT 225 (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Aug 2013 Results published in a Biotron media release.
    • 08 Aug 2013 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 04 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top